

AlloSkin™

SPLIT-THICKNESS DERMIS



The Natural Choice for Wound Healing

AlloSkin is a meshed human dermal allograft for clinical treatment of acute, traumatic/surgical and chronic wounds, including diabetic foot ulcers and venous wound ulcers.¹ It provides a biologic protective cover, that allows the patient's body to successfully heal.

It is also useful for critical burn applications prior to autografting to ensure the wound bed is adequately prepared for successful closure.

THE BENEFITS OF ALLOSKIN

Biologic Elements	Contains collagen and growth factors native to human skin, which are essential to the wound healing process ²
Pliable	Contours to the wound bed with conformable tissue
Robust	Allows for allograft suturing or stapling without tearing
Meshed	Encourages fluid drainage from the wound and permits negative pressure transfer
Cost-Effective	Compares favorably with wound healing rates of advanced bioengineered products that can cost up to three times more per application ¹

“When used adjunctively, allografts consistently show clinical increases in **VASCULARITY, DECREASED BACTERIAL CONTAMINATION, AND STIMULATION OF EPITHELIZATION.**”²

AlloSkin™

SPLIT-THICKNESS DERMIS

AlloSkin is subject to extensive serological and microbial testing. It undergoes a controlled-rate freezing process, to cryopreserve the tissue, with the aim of maintaining natural cell morphology.³

AlloSkin SPLIT-THICKNESS DERMIS

MESH	WIDTH	LENGTH	AREA	REF/PRODUCT #
1:1	5 cm	5 cm	25 cm ²	5125-61052
1:1	8 cm	10 cm	80 cm ²	5180-61052
1:1	8 cm	15 cm	120 cm ²	51120-61052

ORDER NOW
800. 557. 3587

AlloSource, a life sciences organization, helps restore patient functionality by transforming the gift of human tissue donation into enhanced medical products that enable a life of movement, health, and wellbeing. We partner with medical professionals and biomedical companies who share our drive for innovation and quality in the use of human tissue allografts for medical advancements. Headquartered in Centennial, Colorado, we have served a global marketplace since 1994. Learn more at allosource.org.

AlloSkin™ Acellular Dermal Substrate is regulated by the FDA under 21 CFR Part 1271 Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). AlloSource is registered with the FDA as a tissue establishment and accredited by the American Association of Tissue Banks.

1. Desman E, Bartow W, Anderson LH. Human skin allografts for patients with diabetic foot ulcers, venous leg ulcers, or surgical/traumatic wounds: A retrospective, descriptive study. *Ostomy Wound Management*. 2015;61(7):16-22.
2. Snyder RJ. Treatment of nonhealing ulcers with allografts. *Clin Dermatol*. 2005;23(4):388-95.
3. Data on file.

INDICATIONS

May be used for temporary coverage or closure of partial and full-thickness wounds, including chronic wounds, burns and traumatic injuries.

SHELF LIFE AND STORAGE

Five-year storage at or below -40° C

HCPCS CODING

Q-4115 AlloSkin, 1 square cm

TISSUE PROCESSING

Processed in aseptic conditions to exacting specifications. Packaged between two non-woven protective gauze pads, one of which can be used to aid in precision application. Cryopreserved to optimize shelf-life.